Can Electronegative LDL Act as a Multienzymatic Complex?

Electronegative LDL (LDL(-)) is a minor form of LDL present in blood for which proportions are increased in pathologies with increased cardiovascular risk. In vitro studies have shown that LDL(-) presents pro-atherogenic properties, including a high susceptibility to aggregation, the ability to indu...

ver descrição completa

Detalhes bibliográficos
Autores: Benitez, Sonia|||0000-0003-3565-0743, Puig Grifol, Núria|||0000-0002-4699-3162, Rives Jimenez, Jose|||0009-0001-5725-9270, Solé, Arnau|||0009-0007-6517-6188, Sánchez Quesada, José Luis|||0000-0003-0224-591X
Tipo de documento: artigo
Data de publicação:2023
País:España
Recursos:Universitat Autònoma de Barcelona
Repositório:Dipòsit Digital de Documents de la UAB
Idioma:inglês
OAI Identifier:oai:ddd.uab.cat:281649
Acesso em linha:https://ddd.uab.cat/record/281649
https://dx.doi.org/urn:doi:10.3390/ijms24087074
Access Level:Acceso aberto
Palavra-chave:Low-density lipoprotein
Modified LDL
Electronegative LDL
Platelet-activating factor acetylhydrolase
Phospholipase C
Sphingomyelinase
Ceramidase
LDL aggregation
Inflammation
id ES_cc9de58a8be71468556acbbca7fb63cb
oai_identifier_str oai:ddd.uab.cat:281649
network_acronym_str ES
network_name_str España
repository_id_str
spelling Can Electronegative LDL Act as a Multienzymatic Complex?Benitez, Sonia|||0000-0003-3565-0743Puig Grifol, Núria|||0000-0002-4699-3162Rives Jimenez, Jose|||0009-0001-5725-9270Solé, Arnau|||0009-0007-6517-6188Sánchez Quesada, José Luis|||0000-0003-0224-591XLow-density lipoproteinModified LDLElectronegative LDLPlatelet-activating factor acetylhydrolasePhospholipase CSphingomyelinaseCeramidaseLDL aggregationInflammationElectronegative LDL (LDL(-)) is a minor form of LDL present in blood for which proportions are increased in pathologies with increased cardiovascular risk. In vitro studies have shown that LDL(-) presents pro-atherogenic properties, including a high susceptibility to aggregation, the ability to induce inflammation and apoptosis, and increased binding to arterial proteoglycans; however, it also shows some anti-atherogenic properties, which suggest a role in controlling the atherosclerotic process. One of the distinctive features of LDL(-) is that it has enzymatic activities with the ability to degrade different lipids. For example, LDL(-) transports platelet-activating factor acetylhydrolase (PAF-AH), which degrades oxidized phospholipids. In addition, two other enzymatic activities are exhibited by LDL(-). The first is type C phospholipase activity, which degrades both lysophosphatidylcholine (LysoPLC-like activity) and sphingomyelin (SMase-like activity). The second is ceramidase activity (CDase-like). Based on the complementarity of the products and substrates of these different activities, this review speculates on the possibility that LDL(-) may act as a sort of multienzymatic complex in which these enzymatic activities exert a concerted action. We hypothesize that LysoPLC/SMase and CDase activities could be generated by conformational changes in apoB-100 and that both activities occur in proximity to PAF-AH, making it feasible to discern a coordinated action among them. 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/281649https://dx.doi.org/urn:doi:10.3390/ijms24087074reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengMinisterio de Economía y Competitividad https://doi.org/10.13039/501100003329 PI13/00364Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 PI16/00471Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI019/00421Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI20/00334Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 FI20/00252Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 CB07/08/0016Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD21/0006/0006Agència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2017/SGR-1149open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2816492026-06-06T12:50:31Z
dc.title.none.fl_str_mv Can Electronegative LDL Act as a Multienzymatic Complex?
title Can Electronegative LDL Act as a Multienzymatic Complex?
spellingShingle Can Electronegative LDL Act as a Multienzymatic Complex?
Benitez, Sonia|||0000-0003-3565-0743
Low-density lipoprotein
Modified LDL
Electronegative LDL
Platelet-activating factor acetylhydrolase
Phospholipase C
Sphingomyelinase
Ceramidase
LDL aggregation
Inflammation
title_short Can Electronegative LDL Act as a Multienzymatic Complex?
title_full Can Electronegative LDL Act as a Multienzymatic Complex?
title_fullStr Can Electronegative LDL Act as a Multienzymatic Complex?
title_full_unstemmed Can Electronegative LDL Act as a Multienzymatic Complex?
title_sort Can Electronegative LDL Act as a Multienzymatic Complex?
dc.creator.none.fl_str_mv Benitez, Sonia|||0000-0003-3565-0743
Puig Grifol, Núria|||0000-0002-4699-3162
Rives Jimenez, Jose|||0009-0001-5725-9270
Solé, Arnau|||0009-0007-6517-6188
Sánchez Quesada, José Luis|||0000-0003-0224-591X
author Benitez, Sonia|||0000-0003-3565-0743
author_facet Benitez, Sonia|||0000-0003-3565-0743
Puig Grifol, Núria|||0000-0002-4699-3162
Rives Jimenez, Jose|||0009-0001-5725-9270
Solé, Arnau|||0009-0007-6517-6188
Sánchez Quesada, José Luis|||0000-0003-0224-591X
author_role author
author2 Puig Grifol, Núria|||0000-0002-4699-3162
Rives Jimenez, Jose|||0009-0001-5725-9270
Solé, Arnau|||0009-0007-6517-6188
Sánchez Quesada, José Luis|||0000-0003-0224-591X
author2_role author
author
author
author
dc.subject.none.fl_str_mv Low-density lipoprotein
Modified LDL
Electronegative LDL
Platelet-activating factor acetylhydrolase
Phospholipase C
Sphingomyelinase
Ceramidase
LDL aggregation
Inflammation
topic Low-density lipoprotein
Modified LDL
Electronegative LDL
Platelet-activating factor acetylhydrolase
Phospholipase C
Sphingomyelinase
Ceramidase
LDL aggregation
Inflammation
description Electronegative LDL (LDL(-)) is a minor form of LDL present in blood for which proportions are increased in pathologies with increased cardiovascular risk. In vitro studies have shown that LDL(-) presents pro-atherogenic properties, including a high susceptibility to aggregation, the ability to induce inflammation and apoptosis, and increased binding to arterial proteoglycans; however, it also shows some anti-atherogenic properties, which suggest a role in controlling the atherosclerotic process. One of the distinctive features of LDL(-) is that it has enzymatic activities with the ability to degrade different lipids. For example, LDL(-) transports platelet-activating factor acetylhydrolase (PAF-AH), which degrades oxidized phospholipids. In addition, two other enzymatic activities are exhibited by LDL(-). The first is type C phospholipase activity, which degrades both lysophosphatidylcholine (LysoPLC-like activity) and sphingomyelin (SMase-like activity). The second is ceramidase activity (CDase-like). Based on the complementarity of the products and substrates of these different activities, this review speculates on the possibility that LDL(-) may act as a sort of multienzymatic complex in which these enzymatic activities exert a concerted action. We hypothesize that LysoPLC/SMase and CDase activities could be generated by conformational changes in apoB-100 and that both activities occur in proximity to PAF-AH, making it feasible to discern a coordinated action among them.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/281649
https://dx.doi.org/urn:doi:10.3390/ijms24087074
url https://ddd.uab.cat/record/281649
https://dx.doi.org/urn:doi:10.3390/ijms24087074
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 PI13/00364
Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 PI16/00471
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI019/00421
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI20/00334
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 FI20/00252
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 CB07/08/0016
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD21/0006/0006
Agència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2017/SGR-1149
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419736114135040
score 15,300719

Registros relacionados